paclitaxel
RxCUI 56946
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Paclitaxel
Paclitaxel, an alkaloid derived from the Pacific yew, and sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection. There is also an albumin-bound formulation. Common side effects include hair loss, bone marrow suppression, numbness, allergic reactions, muscle pains, and diarrhea. Other side effects include heart problems, increased risk of infection, and lung inflammation. There are concerns that use during pregnancy may cause birth defects. Paclitaxel is in the taxane family of medications. It works by interference with the normal function of microtubules during cell division. Paclitaxel was isolated in 1971 from the Pacific yew and approved for medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It has been made from precursors, and through cell culture.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
40 shownConditions being studied
Research locations
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.